Biotech · Private company
Aptabio Therapeutics, Inc.
Track this companyFree. Adds Aptabio Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials31 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- APX-115Phase 2 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- Isuzinaxib (APX-115)Phase 2 · Contrast Induced Acute Kidney InjuryClinicalTrials.gov · fetched Nov 12, 2026
- ABF-101Phase 1 · Age Related Macular Degeneration (ARMD)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending DosesPHASE1 · RECRUITING · started Feb 1, 2026ClinicalTrials.gov NCT07330674 · fetched Nov 12, 2026
- Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCIPHASE2 · COMPLETED · started Dec 27, 2023ClinicalTrials.gov NCT05758896 · fetched Nov 12, 2026
- A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.PHASE2 · TERMINATED · started Oct 20, 2021ClinicalTrials.gov NCT04880109 · fetched Nov 12, 2026